BioCentury | Jun 7, 2019
Company News

June 6 Company Quick Takes: Take two for Celgene's ozanimod; plus Protalix, ABPI, Axovant and Mylan

Celgene resubmits NDA for ozanimod FDA and EMA accepted submissions from Celgene Corp. (NASDAQ:CELG) for ozanimod to treat multiple sclerosis. The PDUFA date for the selective S1PR1 and S1PR5 modulator is March 25, 2020, and...
BioCentury | May 28, 2019
Distillery Therapeutics

LTB4 as a therapy for influenza A infection

...2019 doi:10.1038/s41564-019-0444-3 CONTACT: Maziar Divangahi, McGill University, Montreal, Que. e-mail: maziar.divangahi@mcgill.ca Elizabeth S. Eaton McGill University Leukotriene B4 (LTB4) Leukotriene B4 type 1 receptor (BLT1) (LTB4R) Influenza...
BioCentury | Apr 26, 2019
Clinical News

Akari's Nomacopan reduces skin inflammation in Phase II

...C5 - Complement 5; LTB4 - Leukotriene B4 Elizabeth S. Eaton, Staff Writer Coversin Akari Therapeutics plc Complement 5 (C5) Leukotriene B4 type 1 receptor (BLT1) (LTB4R) Nomacopan...
BioCentury | Apr 5, 2019
Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
BioCentury | Dec 21, 2018
Clinical News

Benitec's BB-401 misses Stage 1 response threshold in Phase II for head and neck cancer

Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) said an initial analysis of the 12-patient Stage 1 cohort in a Phase II trial to treat recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) showed...
BioCentury | Dec 14, 2018
Clinical News

Axovant discontinues development of nelotanserin after Phase II readout

Axovant Sciences Ltd. (NASDAQ:AXON) discontinued development of nelotanserin after the product missed the primary endpoint in a Phase II trial to treat REM sleep behavior disorder in patients with Lewy body dementia. The double-blind trial...
BioCentury | Aug 11, 2018
Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
BioCentury | Jul 13, 2018
Company News

Axovant gets rights to Benitec's gene therapy BB-301

Axovant Sciences Ltd. (NASDAQ:AXON) broadened its gene therapy pipeline by obtaining exclusive, worldwide rights from Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) to BB-301. Axovant plans to start a placebo-controlled clinical trial next year of the gene...
BioCentury | Jul 9, 2018
Company News

Axovant deepens gene therapy pipeline with Benitec deal

Axovant Sciences Ltd. (NASDAQ:AXON) broadened its gene therapy pipeline by obtaining exclusive, worldwide rights from Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) to BB-301. Axovant plans to start a placebo-controlled clinical trial next year of the gene...
BioCentury | Mar 9, 2018
Clinical News

Phase I/II of Roche PNH candidate temporarily halted

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said enrollment was temporarily stopped in the Phase I/II COMPOSER trial evaluating RG6107 (SKY59) in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH) after two patients who received RG6107...
Items per page:
1 - 10 of 197